To evaluate the effectiveness and safety of blinatumomab maintenance therapy following allogeneic hematopoietic cell transplantation in patients with B-lineage acute lymphoblastic leukemia.
Long-term follow-up study focusing on blinatumomab therapy after allogeneic transplantation for B-lineage ALL.
Assessment of patient outcomes regarding disease relapse and overall survival post-transplantation.
Reduction in disease relapse rates among patients receiving blinatumomab maintenance therapy.
Improved overall survival observed in the cohort receiving maintenance therapy compared to historical controls.